# Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02172456** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** 99mTc-radiolabelled tiotropium
- **DRUG:** non-radiolabelled tiotropium

## Key facts

- **NCT ID:** NCT02172456
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2002-10
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172456, "Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02172456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*